Dr. Wang on the Evolution of Ibrutinib in the Treatment Landscape of MCL

In Partnership With:

Partner | Cancer Centers | <b>MD Anderson</b>

Michael Wang, MD, discusses the evolution of ibrutinib in the treatment landscape of mantle cell lymphoma.

Michael Wang, MD, professor, Departments of Lymphoma/Myeloma and Stem Cell Transplantation and Cellular Therapy, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the evolution of ibrutinib (Imbruvica) in the treatment landscape of mantle cell lymphoma (MCL).

Ibrutinib has been utilized for many years following its approval for relapsed MCL in November 2013, Wang explains. Moreover, Wang began implementing the agent in practice prior to its approval, he adds. Additionally, Wang says he has studied Ibrutinib and other agents, specifically regarding the mechanism of resistance caused by ibrutinib and other BTK inhibitors.

Other clinical trials have explored the utility of ibrutinib in MCL, further increasing its potential within the space, Wang continues. The agent has been utilized in various relapse settings of MCL, Wang concludes.